DrugPatentWatch Database Preview

Details for Patent: 7,229,613

« Back to Dashboard

Which drugs does patent 7,229,613 protect, and when does it expire?

Patent 7,229,613 protects WELCHOL and is included in two NDAs.

Protection for WELCHOL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-nine patent family members in seventeen countries.

Summary for Patent: 7,229,613

Title:	Method for lowering serum glucose
Abstract:	A method for treating hyperglycemia and/or reducing serum glucose levels in a patient that includes administering to the patient a therapeutically effective amount of an amine polymer is disclosed. In one embodiment, the amine polymer is aliphatic. Examples of polymers useful in an embodiment of the invention include sevelamer hydrogen chloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula: ##STR00001## and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that lowers serum glucose.
Inventor(s):	Burke; Steven K. (Sudbury, MA), Donovan; Joanne M. (Needham, MA)
Assignee:	Genzyme Corporation (Cambridge, MA)
Application Number:	10/125,700
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 7,229,613

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Daiichi Sankyo	WELCHOL	colesevelam hydrochloride	FOR SUSPENSION;ORAL	022362-001	Oct 2, 2009		RX	Yes	No					Y
Daiichi Sankyo	WELCHOL	colesevelam hydrochloride	FOR SUSPENSION;ORAL	022362-002	Oct 2, 2009		RX	Yes	Yes					Y
Daiichi Sankyo	WELCHOL	colesevelam hydrochloride	TABLET;ORAL	021176-001	May 26, 2000	AB	RX	Yes	Yes					Y

Non-Orange Book US Patents Family Members for Patent 7,229,613

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,377,428	Low salt forms of polyallylamine
7,261,880	Methods of treating Syndrome X with aliphatic polyamines
7,541,024	Low salt forms of polyallylamine

International Family Members for US Patent 7,229,613

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	331525
Austria	380553
Austria	390927
Australia	2002252632